Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement boost or blunt your painkiller?

NCT ID NCT02206178

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This early-phase trial in healthy men aged 18 to 45 asks whether taking N-acetylcysteine alongside acetaminophen (paracetamol) changes the drug's pain-relieving effect. Participants receive either the combination or a placebo, and researchers measure pain intensity from heat stimuli before and after dosing. The study also looks at whether genetic differences in an enzyme called GSH influence the effect. The goal is to understand how these two common substances interact, which could inform future pain treatment approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-acetylcysteine combined with acetaminophen
What this could lead to
If N-acetylcysteine is found to alter acetaminophen's pain relief, it could guide safer or more effective pain management strategies.
What could go wrong
This is a small, early-phase study in healthy volunteers, so results may not apply to real-world pain patients. The effect may also vary by genetics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

24 people

The number who actually took part.

Start date

Sep 2013

Finished

Jan 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male * Between 18 and 45 years old * Without treatment during the 7 days before inclusion specially no use of antalgic and anti-inflammatory * Cooperation and understanding enough to conform to the study obligations -Having given free, informed written consent * Affiliated at system of French social security * Inscription or acceptation of inscription in the national register of volunteers involved in trials. Exclusion Criteria: * Patient with one or many contraindication for the administration of the trial's products, * Patient that have taken N-acetylcysteine as bronchial thinner during the last 3 days, * Patient with medical or surgical history judged by the investigator or his representative as being not compatible with the clinical trial * Patient with disease progression during inclusion, * Patient with excessive consumption of alcohol, tobacco (+ than 10 cigarette/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cup a day) or any addiction to drugs, * Patient with a heat pain mean threshold during training higher or equal to 46.5°C, * Patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial, * Patient with cooperation and understanding that do not allow him to follow the trial, * Patients with minor or under guardianship, * No affiliation at system of French social security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.